CA 15-3 II

Cancer Antigen 15-3

cobas®

REF	Σ		SYSTEM
			Elecsys 2010
			MODULAR ANALYTICS E170
03045838 122	100		**cobas e** 411
			cobas e 601
			cobas e 602

English

> **Please note**
>
> The measured CA 15-3 value of a patient's sample can vary depending on the testing procedure used. The laboratory finding must therefore always contain a statement on the CA 15-3 assay method used. CA 15-3 values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. If there is a change in the CA 15-3 assay procedure used while monitoring therapy, then the CA 15-3 values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both methods.

Intended use

Immunological in vitro assay for quantitative determination of CA 15-3 in human serum and plasma to aid in the management of breast cancer patients. In conjunction with other clinical and diagnostic procedures, serial testing with this assay is an aid

- in the early detection of recurrence in previously treated stage II and III breast cancer patients
- for monitoring response to therapy in metastatic breast cancer patients

The **e**lectro**c**hemi**l**uminescence **i**mmun**o****a**ssay "ECLIA" is intended for use on Elecsys and **cobas e** immunoassay analyzers.

Summary

The CA 15-3 values measured are defined by the use of the monoclonal antibodies (MAb) 115D8 and DF3 in a sandwich assay. MAb 115D8 is directed against human milk fat globule membranes,[1,2] whereas MAb DF3 is directed against the membrane fraction from human metastatic breast cancer.[3]

The 115D8 and DF3-reactive determinants detected by the test are located on a glycoprotein having a molecular weight of > 400 kDa. The antigen is termed MAM-6 and belongs to a subgroup of sialylated glycoproteins designated polymorphic epithelial mucin (PEM). Polymorphic epithelial mucins (PEMs) are normally found in the luminal secretion of glandular cells and do not circulate in the blood. When cells become malignant and their basal membranes permeable, PEMs are detectable in serum using the CA 15-3 assay.[4]

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 20 µL of sample are automatically prediluted 1:10 with Diluent Universal. The antigen (in 20 µL of prediluted sample), a biotinylated monoclonal CA 15-3-specific antibody, and a monoclonal CA 15-3-specific antibody labeled with a ruthenium complex[a] react to form a sandwich complex.

- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.

- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex ($Ru(bpy)_3^{2+}$)

Reagents - working solutions

The reagent rackpack is labeled as CA 15-3 II.

M   Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.

R1   Anti-CA 15-3-Ab~biotin (gray cap), 1 bottle, 10 mL:
Biotinylated monoclonal antibody (115D8; mouse) 1.75 mg/L; phosphate buffer 20 mmol/L, pH 6.0; preservative.

R2   Anti-CA 15-3-Ab~$Ru(bpy)_3^{2+}$ (black cap), 1 bottle, 10 mL:
Monoclonal anti-CA 15-3 antibody (DF3; mouse) labeled with ruthenium complex 10 mg/L; phosphate buffer 100 mmol/L, pH 7.0; preservative.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines.

Safety data sheet available for professional user on request.

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is read in from the respective reagent barcodes.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	12 weeks
on the analyzers	5 weeks

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-, Na-, NH_4^+-heparin and K_3-EDTA plasma.

Results obtained when using sodium citrate plasma are about 24 % lower than compared to those obtained with serum.

Criterion: Recovery within 90-110 % of serum value or slope 0.9-1.1 + intercept within < ± 2x analytical sensitivity (LDL) + coefficient of correlation > 0.95.

Stable for 5 days at 2-8 °C, 3 months at -20 °C.[5]

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

ms_03045838122V19.0

CA 15-3 II

Cancer Antigen 15-3

cobas®

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples, calibrators and controls on the analyzers should be analyzed/measured within 2 hours.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 03045846122, CA 15-3 II CalSet, 4 x 1 mL

- [REF] 11776452122, PreciControl Tumor Marker, for 2 x 3 mL each of PreciControl Tumor Marker 1 and 2

- [REF] 11732277122, Diluent Universal, 2 x 16 mL sample diluent or [REF] 03183971122, Diluent Universal, 2 x 36 mL sample diluent

- General laboratory equipment

- Elecsys 2010, MODULAR ANALYTICS E170 or **cobas e** analyzer

Accessories for Elecsys 2010 and **cobas e** 411 analyzers:

- [REF] 11662988122, ProCell, 6 x 380 mL system buffer

- [REF] 11662970122, CleanCell, 6 x 380 mL measuring cell cleaning solution

- [REF] 11930346122, Elecsys SysWash, 1 x 500 mL washwater additive

- [REF] 11933159001, Adapter for SysClean

- [REF] 11706802001, Elecsys 2010 AssayCup, 60 x 60 reaction vessels

- [REF] 11706799001, Elecsys 2010 AssayTip, 30 x 120 pipette tips

Accessories for MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers:

- [REF] 04880340190, ProCell M, 2 x 2 L system buffer

- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution

- [REF] 03023141001, PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use

- [REF] 03005712190, ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change

- [REF] 12102137001, AssayTip/AssayCup Combimagazine M, 48 magazines x 84 reaction vessels or pipette tips, waste bags

- [REF] 03023150001, WasteLiner, waste bags

- [REF] 03027651001, SysClean Adapter M

Accessories for all analyzers:

- [REF] 11298500316, Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Calibration

Traceability: This method has been standardized against the Elecsys CA 15-3 assay. This in turn has been standardized against the Enzymun-Test CA 15-3 method and CA 15-3 RIA by Fujirebio Diagnostics.

Every Elecsys reagent set has a barcoded label containing specific information for calibration of the particular reagent lot. The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot

- after 7 days (when using the same reagent kit on the analyzer)

- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Tumor Marker.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in U/mL or kU/L).

Limitations - interference

The assay is unaffected by icterus (bilirubin < 1112 µmol/L or < 65 mg/dL), hemolysis (Hb < 1.9 mmol/L or < 3.0 g/dL), lipemia (Intralipid < 1500 mg/dL) and biotin (< 409 nmol/L or < 100 ng/mL).

Criterion: Recovery within ± 10 % of initial value.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

No interference was observed from rheumatoid factors up to a concentration of 1500 IU/mL.

Typically, no high-dose hook effect[b] can be observed at CA 15-3 concentrations up to 20000 U/mL. However, due to the heterogeneous nature of the CA 15-3 antigen a high-dose hook effect below this value cannot be completely excluded. In case of an unexpected low result, the sample should be diluted 1:10 (refer to chapter "Dilution") and tested again.

In vitro tests were performed on 28 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

b) High-dose hook effect: A sample with a true concentration clearly above the measuring range, but found within the measuring range.

Limits and ranges

Measuring range

1.00-300 U/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 1.00 U/mL. Values above the measuring range are reported as > 300 U/mL (or up to 3000 U/mL for 10-fold diluted samples).

Lower limits of measurement

Lower detection limit of the test

Lower detection limit: < 1.00 U/mL

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying two standard deviations above that of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).

Dilution

Use Diluent Universal for automatic sample predilution. Samples with CA 15-3 concentrations above the measuring range despite predilution must be diluted 1:10 with Diluent Universal (either manually for all analyzers or automatically by the MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers). The concentration of the diluted sample must be > 30 U/mL.

After manual dilution, multiply the result by the dilution factor.

CA 15-3 II

Cancer Antigen 15-3

cobas®

After dilution by the analyzers, the MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 software automatically takes the dilution into account when calculating the sample concentration.

Expected values

• *Healthy subjects:*

Results of a reference range study using a panel of samples from 378 apparently healthy non-pregnant females (Roche study No. RD000788)

Percentile (%)	U/mL	Confidence interval (U/mL)
95	26.4	25.2-27.9
97.5	28.5	26.9-34.5
99	34.5	28.7-57.8

• *Patients with benign diseases and pregnant women:*

Relative distribution of CA 15-3 concentrations in patients with benign disease and pregnancy

	Subjects total	< 25 U/mL	25-50 U/mL	> 50-200 U/mL	> 200 U/mL
	N	Classification in percent (%)			
Liver, pancreas, gall bladder	109	84	16	0	0
Breast	58	88	12	0	0
Gynecological diseases	42	83	12	5	0
Renal failure	37	81	19	0	0
Urological diseases	34	82	18	0	0
Bacterial infection	28	96	4	0	0
Pregnancy	34	97	0	3	0

• *Patients with malignant diseases (others than breast):*

Relative distribution of CA 15-3 concentrations in individuals with malignancy other than breast

	Subjects total	< 25 U/mL	25-50 U/mL	> 50-200 U/mL	> 200 U/mL
	N	Classification in percent (%)			
Stomach-Ca[c]	36	75	14	8	3
Hepatocellular-Ca	37	60	32	3	5
Lung-Ca	38	82	13	5	0
Ovarian-Ca	34	47	21	29	3
Gynecological-Ca	5	40	20	40	0
Prostate-Ca	48	79	17	4	0
Colorectal-Ca	40	93	7	0	0
Pancreatic-Ca	40	65	33	2	0

c) Ca = Carcinoma

• *Patients with breast cancer:*

Relative distribution of CA 15-3 concentrations in patients with breast malignancy. The staging of patients according to UICC criteria was performed at primary diagnosis before any treatment. The patients diagnosed with recurrent disease had developed metastases (M1).

	Subjects total	< 25 U/mL	25-50 U/mL	> 50-200 U/mL	> 200 U/mL
	N	Classification in percent (%)			
UICC I	56	88	12	0	0
UICC II	126	85	13	2	0

	Subjects total	< 25 U/mL	25-50 U/mL	> 50-200 U/mL	> 200 U/mL
	N	Classification in percent (%)			
UICC III	77	53	30	14	3
UICC IV	24	25	17	37	21
Recurrent Disease	75	15	25	36	24

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in accordance with a modified protocol (EP5-A) of the CLSI (Clinical and Laboratory Standards Institute): 6 times daily for 10 days (n = 60); repeatability on MODULAR ANALYTICS E170 analyzer, n = 21. The following results were obtained:

Elecsys 2010 and **cobas e** 411 analyzers					
		Repeatability		Intermediate precision	
Sample	Mean U/mL	SD U/mL	CV %	SD U/mL	CV %
Human serum 1	38.0	0.81	2.1	1.38	3.6
Human serum 2	85.5	2.72	3.2	3.66	4.3
Human serum 3	179	4.56	2.6	6.60	3.7
PreciControl TM[d]1	24.5	0.62	2.5	0.87	3.6
PreciControl TM2	67.6	2.48	3.7	2.83	4.2

d) TM = Tumor Marker

MODULAR ANALYTICS E170, **cobas e** 601 and **cobas e** 602 analyzers						
	Repeatability			Intermediate precision		
Sample	Mean U/mL	SD U/mL	CV %	Mean U/mL	SD U/mL	CV %
Human serum 1	18.9	0.24	1.3	20.1	0.64	3.2
Human serum 2	76.4	1.07	1.4	79.0	3.08	3.9
Human serum 3	148	1.72	1.2	156	7.75	5.0
PreciControl TM1	20.3	0.24	1.2	21.3	0.89	4.2
PreciControl TM2	47.6	0.70	1.5	49.6	1.82	3.7

Method comparison

A comparison of the Elecsys CA 15-3 II assay (y) with the Elecsys CA 15-3 assay (x) using clinical samples gave the following correlations:

Number of samples measured: 52

Passing/Bablok regression[6]

Slope: 1.06 (95 % confidence range: 1.01-1.15)

Intercept: 2.66 (95 % confidence range: -0.99-5.97)

Coefficient of correlation: 0.965

The sample concentrations were between approximately 6 and 280 U/mL.

Analytical specificity

The Elecsys CA 15-3 II tumor marker assay is based on the monoclonal 115D8 and DF3 antibodies which are only available from Fujirebio Diagnostics, its licensees and its representatives. The performance characteristics of test procedures using these antibodies cannot be assumed for test methods using other antibodies.

CA 15-3 II

Cancer Antigen 15-3

cobas®

Clinical performance in follow-up

Patients diagnosed with breast cancer were examined in a retrospective study (at least 4 samples/patient during follow-up study) and classified according to progression/recurrence, regression/response or no change of disease based on the clinical information (medical imaging and other clinical investigations). The CA 15-3 concentrations were measured in parallel and from their relative change, marker-increase (defined as > 25 % and resulting in values > 10 U/mL after increase) and marker-decrease (by > 25 %) were determined.

Early detection of recurrence

Of 44 patients previously diagnosed and treated for stage II or stage III breast cancer (no evidence of disease at the beginning of the follow-up study), 20 had recurrence of disease according to clinical symptoms. Of these, 18 (90 %) had CA 15-3 levels that increased by > 25 %. Of the 24 patients that did not experience recurrence, 17 (71 %) had CA 15-3 levels that remained the same (within 25 %) or decreased.

Table for early detection of recurrence:

		Clinical diagnosis: Recurrence of disease		
		Yes	No	Total
CA 15-3 increase > 25 %	Yes	18	7	25
	No	2	17	19
	Total	20	24	44

The corresponding results for positive predictive value (PPV) and negative predictive value (NPV) with the 95 % confidence interval as derived from the table are:

Positive predictive value: 72 % (50-87 %)

Negative predictive value: 90 % (66-98 %)

Monitoring response to therapy

Of 60 patients diagnosed with metastatic breast cancer, 23 responded to therapy as determined by clinical criteria. Of these, 18 (78 %) had CA 15-3 levels that decreased by > 25 %. Of the 37 patients that did not respond to therapy, 29 (78 %) had levels of CA 15-3 that remained the same (within 25 %) or increased.

Table for response to therapy:

		Clinical diagnosis: Response to therapy		
		Yes	No	Total
CA 15-3 decrease > 25 %	Yes	18	8	26
	No	5	29	34
	Total	23	37	60

The corresponding results for positive predictive value (PPV) and negative predictive value (NPV) with the 95 % confidence interval as derived from the table are:

Positive predictive value: 69 % (48-85 %)

Negative predictive value: 85 % (68-95 %)

References

1   Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland. Prot Biol Fluids 1982;29:813-816.

2   Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206.

3   Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor. Hybridoma 1984;(3):223-232.

4   Sekine H, Ohno T, Kufe DW. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985;135(5):3610-3615.

5   Guder WG, Narayanan S, Wisser H, et al. List of Analytes; Preanalytical Variables. Brochure in: Samples: From the Patient to the Laboratory. GIT-Verlag, Darmstadt 1996;8. ISBN 3-928865-22-6:8-9.

6   Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

FUJIREBIO Diagnostics, Inc.   CA 15-3 is a registered trademark of Fujirebio Diagnostics, Inc.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT	Contents of kit
SYSTEM	Analyzers/Instruments on which reagents can be used
REAGENT	Reagent
CALIBRATOR	Calibrator
→	Volume after reconstitution or mixing

CE

Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

⬡ Roche